GENBIOPRO, INC.

Lobbying client · Nevada · filed 2025 to 2026

Generic Pharmaceutical Manufacturer

$140,000 Reported spend

7 Filings counted

1 Outside firm hired

0 Bills named

Spend is reported income plus in-house expenses across 7 filings. Everything on this page comes from one LDA client record (52117), filed by the registrant listed below.

Who filed for this client 1

EMERGENT STRATEGIES $140,000 Outside firm · 7 filings

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

Reported by year 2 years

2026 $0 3 filings
2025 $140,000 4 filings

Issues lobbied 3

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 2

HOUSE OF REPRESENTATIVES 7
SENATE 7

Recent filings 7 total

Q3 report

EMERGENT STRATEGIES

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · posted Oct 21, 2026

View → Q2 report

EMERGENT STRATEGIES

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · posted Jul 17, 2026

View → Q1 report

EMERGENT STRATEGIES

1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · posted Apr 20, 2026

View → Q4 report

EMERGENT STRATEGIES

4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $35,000 income · posted Jan 20, 2026

View → Q3 report

EMERGENT STRATEGIES

3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $35,000 income · posted Oct 20, 2025

View → Q2 report

EMERGENT STRATEGIES

2nd Quarter 2025 (Apr 1 - June 30) · House · Senate · $35,000 income · posted Jul 21, 2025

View → Q1 report

EMERGENT STRATEGIES

1st Quarter 2025 (Jan 1 - Mar 31) · House · Senate · $35,000 income · posted Apr 21, 2025

View →

Keep going

Filings through October 21, 2026, the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.